Dizal (Jiangsu) Pharmaceutical 대차 대조표 상태

재무 상태 기준 확인 3/6

Dizal (Jiangsu) Pharmaceutical 의 총 주주 지분은 CN¥437.2M 이고 총 부채는 CN¥819.6M, 이는 부채 대 자기자본 비율을 187.4% 로 가져옵니다. 총자산과 총부채는 각각 CN¥1.6B 및 CN¥1.2B 입니다.

주요 정보

187.4%

부채 비율

CN¥819.58m

부채

이자 보상 비율	n/a
현금	CN¥808.30m
주식	CN¥437.25m
총 부채	CN¥1.21b
총 자산	CN¥1.64b

최근 재무 상태 업데이트

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Aug 20

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Apr 30

Recent updates

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Aug 20

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

May 02

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Apr 30

재무 상태 분석

단기부채: 688192 의 단기 자산 ( CN¥976.9M )이 단기 부채( CN¥566.9M ).

장기 부채: 688192 의 단기 자산( CN¥976.9M )이 장기 부채( CN¥638.4M ).

부채 대 자본 내역 및 분석

부채 수준: 688192 의 순부채 대 자기자본 비율( 2.6% )은 satisfactory로 간주됩니다.

부채 감소: 688192 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 187.4% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: 688192 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 688192 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

Dizal (Jiangsu) Pharmaceutical 대차 대조표 상태

재무 상태 기준 확인 3/6

주요 정보

최근 재무 상태 업데이트

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Recent updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Price target increased by 7.4% to CN¥56.00

Dizal Receives Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

NMPA Approves Burning Rock and Dizal's First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

New minor risk - Share price stability

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Consensus revenue estimates decrease by 12%

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

New minor risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

Consensus EPS estimates fall by 13%

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology

New major risk - Revenue and earnings growth

Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting

Price target increased by 11% to CN¥56.42

Dizal Announces Center for Drug Evaluation Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

Less than half of directors are independent

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC

Dizal Pharmaceutical Announces Pre-Clinical and Clinical Results of Sunvozertinib (DZD9008) Published in Cancer Discovery

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for Dzd4205 for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 (Sunvozertinib) for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기